Robert R Zielinski
Overview
Explore the profile of Robert R Zielinski including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
10
Citations
674
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Conduit C, Inderjeeth A, Allen R, Martin A, Parulekar W, Mulroe E, et al.
Future Oncol
. 2025 Jan;
21(6):627-636.
PMID: 39819293
No abstract available.
2.
Sweeney C, Martin A, Stockler M, Begbie S, Cheung L, Chi K, et al.
Lancet Oncol
. 2023 Mar;
24(4):323-334.
PMID: 36990608
Background: The interim analysis of the ENZAMET trial of testosterone suppression plus either enzalutamide or standard nonsteroidal antiandrogen therapy showed an early overall survival benefit with enzalutamide. Here, we report...
3.
Stockler M, Martin A, Davis I, Dhillon H, Begbie S, Chi K, et al.
J Clin Oncol
. 2021 Dec;
40(8):837-846.
PMID: 34928708
Purpose: We previously reported that enzalutamide improved overall survival when added to standard of care in metastatic, hormone-sensitive prostate cancer. Here, we report its effects on aspects of health-related quality...
4.
Maio M, Carlino M, Joshua A, McWhirter E, Ribas A, Ascierto P, et al.
Eur J Cancer
. 2021 Nov;
160:1-11.
PMID: 34801354
Objectives: Parts 4 and 5 of the phase 1/2 KEYNOTE-022 study investigated the maximum tolerated dose (MTD), safety, and efficacy of pembrolizumab plus trametinib in solid tumours and BRAF wild-type...
5.
Sweeney C, Martin A, Stockler M, Begbie S, Chi K, Chowdhury S, et al.
Eur Urol
. 2021 May;
80(3):275-279.
PMID: 34030924
Men who initially present with localized prostate cancer and later develop metachronous metastases have a better prognosis than men with de novo metastatic disease and often have a low burden...
6.
Davis I, Martin A, Stockler M, Begbie S, Chi K, Chowdhury S, et al.
N Engl J Med
. 2019 Jun;
381(2):121-131.
PMID: 31157964
Background: Enzalutamide, an androgen-receptor inhibitor, has been associated with improved overall survival in men with castration-resistant prostate cancer. It is not known whether adding enzalutamide to testosterone suppression, with or...
7.
Barnet M, Zielinski R, Warby A, Lewis C, Kao S
J Thorac Oncol
. 2017 Sep;
13(1):e1-e2.
PMID: 28919393
No abstract available.
8.
Zielinski R, Azad A, Chi K, Tyldesely S
Can Urol Assoc J
. 2014 Sep;
8(7-8):E520-3.
PMID: 25210555
Introduction: Utilization of docetaxel in patients with metastatic castration resistant prostate cancer (mCRPC) remains low despite its demonstrated survival benefit. In a population-based cohort, we sought to determine whether the...
9.
Zielinski R, Eigl B, Chi K
Cancer J
. 2013 Jan;
19(1):79-89.
PMID: 23337761
Important inroads have been made in the understanding and treatment of metastatic prostate cancer in recent years. However, the need for agents targeting novel pathways remains ever present. One such...
10.
Gallagher G, Huang Y, Zielinski R, Morita S, Hunyor S
ASAIO J
. 2007 May;
53(3):292-7.
PMID: 17515717
The HeartPatch direct cardiac compression device consists of two separate, nonsurround patches placed on the left and right ventricular free walls. Although the device has been shown to effectively restore...